A Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Orally Administered DA-7503 After Single and Multiple Ascending Dose Regimens in Healthy Adult and Elderly Participants
Latest Information Update: 06 May 2024
At a glance
- Drugs DA 7503 (Primary)
- Indications Alzheimer's disease; Tauopathies
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 06 May 2024 New trial record